Core Insights - Inspire Medical Systems (INSP) is positioned for growth due to a significant product transition, with management highlighting clinical momentum, improved reimbursement visibility, and disciplined cost control, despite facing near-term challenges related to inventory conversion and competition [2][12][14] Company Overview - Inspire Medical focuses on innovative, minimally-invasive solutions for obstructive sleep apnea, with a market capitalization of $2.81 billion. The company anticipates a 39.1% earnings decline for Q4 2025, but expects earnings growth to resume in 2026 [4] Financial Performance - INSP shares have decreased by 12.5% over the past six months, while the industry has declined by 16.3%, and the S&P 500 has increased by 16.3% during the same period [3] - The company has consistently surpassed earnings estimates in the last four quarters, achieving an average surprise of 164.19% [6] Positive Factors Driving Prospects - The launch of Inspire V is a key growth driver, with strong clinical data supporting its adoption, including reduced surgical times and high nightly usage. Adoption has accelerated, reaching over 75% of implanting centers [7] - Reimbursement trends are favorable, with an 11% increase in the physician fee schedule for CPT 64568 effective January 2026, enhancing the economic viability for hospitals [8][9] - The adoption of GLP-1 therapies is increasing patient flow into sleep clinics, which could lead to more referrals for Inspire Medical as noncompliance with CPAP emerges [10] Operational Discipline - The company has demonstrated operational discipline, achieving earnings upside through gross margin expansion and cost control, despite increased marketing expenses [11] Key Challenges - The transition from Inspire IV to Inspire V presents complexities, with some centers continuing to use Inspire IV for economic reasons, which complicates inventory forecasting [12] - Uncertainty exists around GLP-1 trialing, which may delay surgical interventions and impact short-term volume growth [13] - Elevated operating expenses and competition pose challenges to maintaining margin expansion, as operating expenses growth outpaces revenue growth [14] Estimate Trend - The Zacks Consensus Estimate for earnings in 2025 is $1.71 per share, with Q4 2025 revenue estimated at $262.9 million and a loss per share of 70 cents [15]

Core Viewpoint - Inspire Medical Systems, Inc. is facing a federal securities class action due to allegations of misleading statements regarding the launch and demand for its Inspire V device, leading to significant financial losses for investors [3][5]. Group 1: Allegations and Legal Action - The complaint against Inspire Medical Systems claims that the company and its executives violated federal securities laws by making false or misleading statements about the market demand for the Inspire V device and the steps taken for its launch [3]. - Investors are reminded of the January 5, 2026 deadline to seek the role of lead plaintiff in the class action lawsuit [1][6]. Group 2: Launch Issues and Financial Impact - On August 4, 2025, Inspire Medical announced delays in the launch of the Inspire V device due to incomplete training and onboarding at treatment centers, as well as billing and reimbursement challenges [4]. - The company reported weak demand and excess inventory for the Inspire V, leading to a more than 80% cut in its 2025 earnings guidance [5]. - Following these announcements, Inspire's stock price plummeted over 32% in one day, from $129.95 to $87.91, resulting in a loss of approximately $1.2 billion in market capitalization [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Inspire Medical Systems, Inc. due to allegations of false and misleading statements regarding the launch of its Inspire V device, which has led to significant financial losses for investors [3][5]. Group 1: Legal Investigation - The law firm is reminding investors of the January 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action against Inspire Medical [3]. - The firm encourages investors who suffered losses in Inspire Medical to contact them directly to discuss their legal options [1][9]. Group 2: Company Performance and Issues - Inspire Medical announced significant setbacks in the launch of its Inspire V device on August 4, 2025, citing delays in training and onboarding at treatment centers [6]. - The company faced billing and reimbursement challenges, as necessary software updates for claims processing were not implemented until July 1, 2025, preventing implanting centers from billing for procedures [6]. - Inspire Medical reported weak demand and excess inventory for the Inspire V device, leading to a more than 80% cut in its 2025 earnings guidance [7]. Group 3: Market Impact - Following the announcement of these issues, Inspire Medical's stock price plummeted over 32% in one day, from $129.95 per share on August 4, 2025, to $87.91 per share on August 5, 2025, resulting in a loss of approximately $1.2 billion in market capitalization [7].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Inspire Medical To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Inspire Medical between August 6, 2024 and August 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - D ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Inspire Medical Systems, Inc. due to allegations of misleading statements regarding the launch of its Inspire V device, which has faced significant setbacks and weak demand [2][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Inspire Medical to contact them to discuss their legal options [1]. - A federal securities class action has been filed against Inspire Medical, with a deadline of January 5, 2026, for investors to seek the role of lead plaintiff [2][7]. Group 2: Company Performance and Issues - Inspire Medical announced on August 4, 2025, that the launch of its Inspire V device was delayed due to treatment centers not completing necessary training and onboarding [5]. - The company faced billing and reimbursement challenges, as Medicare's approval of a CPT code for Inspire V did not coincide with the necessary software updates for claims processing [5]. - Inspire Medical reported weak demand and excess inventory for the Inspire V device, leading to a more than 80% cut in its 2025 earnings guidance [6]. Group 3: Market Impact - Following the announcement of setbacks, Inspire Medical's stock price plummeted over 32% in one day, from $129.95 to $87.91, resulting in a loss of approximately $1.2 billion in market capitalization [6].

Core Viewpoint - A securities class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) for allegedly misleading investors about operational failures related to the launch of its Inspire V device for obstructive sleep apnea [1][3]. Group 1: Allegations and Impact - The lawsuit claims that Inspire Medical assured investors of its "operational readiness" for the Inspire V launch, which was later revealed to be false due to undisclosed operational issues [3][4]. - Key operational failures included delays in Medicare claims processing software updates, which did not take effect until July 1, 2025, preventing implanting centers from billing for procedures [4]. - An excess inventory of the older Inspire IV device created a channel glut, negatively impacting demand for the new Inspire V product and leading to a significant cut in 2025 earnings per share (EPS) guidance by over 80% [4]. - Many treatment centers had not completed necessary training and onboarding for the new device, contributing to a $42.04 per share drop in stock value, equating to a 32.4% decline [4]. Group 2: Legal Actions and Investor Guidance - Investors who purchased Inspire Medical securities between August 6, 2024, and August 4, 2025, are encouraged to contact Hagens Berman to discuss their legal rights before the Lead Plaintiff Deadline of January 5, 2026 [2][3]. - Hagens Berman is focusing on the concealment of critical operational issues, emphasizing the impact of management's narrative on the stock's performance [5]. - Whistleblowers with non-public information regarding Inspire are encouraged to assist in the investigation, with potential rewards under the SEC Whistleblower program [6].

Core Viewpoint - A securities class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) for allegedly misleading investors about the operational readiness of its new device, Inspire V, leading to significant financial losses for investors [1][2]. Summary by Relevant Sections Allegations of Misleading Information - Inspire Medical allegedly assured investors of its "operational readiness" for the Inspire V launch, claiming it was ready for full commercial rollout, which concealed critical operational failures [2][4]. - The lawsuit highlights that the necessary software updates for Medicare claims processing did not take effect until July 1, 2025, delaying the rollout and revenue generation [3]. - There was a significant surplus of the older Inspire IV device, which impacted demand for the new Inspire V product, leading to a drastic cut in 2025 EPS guidance by over 80% [3]. Financial Impact - The stock price of Inspire Medical dropped by $42.04 per share, representing a 32.4% decline in value following the revelation of these operational issues [3]. - The lawsuit claims that many treatment centers had not completed the essential training and onboarding required to implant the new device, further complicating the launch [3]. Legal Actions and Investor Rights - Investors who purchased Inspire Medical securities between August 6, 2024, and August 4, 2025, are encouraged to contact Hagens Berman before the January 5, 2026, Lead Plaintiff Deadline to discuss their legal rights [2][4]. - Hagens Berman is focusing on the alleged concealment of critical operational issues, including the Medicare claims software failure and the inventory glut of the prior device [4].

Core Viewpoint - A securities class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) for allegedly misleading investors about the operational readiness of its next-generation device, the Inspire V, leading to significant financial losses for investors [1][3]. Group 1: Allegations and Impact - The lawsuit claims that Inspire Medical assured investors of its operational readiness for the Inspire V launch, stating it was ready for a full commercial rollout, while concealing critical operational failures [3][4]. - Key undisclosed operational issues included delays in Medicare claims processing software updates, which only took effect on July 1, 2025, causing revenue bottlenecks [4]. - An excess inventory of the older Inspire IV device negatively impacted demand for the new Inspire V product, necessitating an inventory "burn down" [4]. - Many treatment centers had not completed the necessary training and onboarding for the new device, further hindering the launch [4]. Group 2: Financial Consequences - The alleged operational failures led Inspire Medical to cut its 2025 earnings per share (EPS) guidance by over 80%, resulting in a significant stock price drop of $42.04 per share, equating to a 32.4% decline in value [4][5]. - The lawsuit highlights that the stock collapse was attributed to management prioritizing a narrative of seamless transition over the actual operational challenges faced [5]. Group 3: Legal and Investigative Actions - Hagens Berman, the law firm leading the investigation, is encouraging investors who suffered losses during the class period from August 6, 2024, to August 4, 2025, to contact them before the January 5, 2026, lead plaintiff deadline [2][3]. - The firm is particularly focused on the concealment of the Medicare claims software failure and the inventory issues related to the Inspire IV device [5].

Partner Reed Kathrein ScrutinizingAllegedConcealment of Billing Code Errors and Inventory Glut Driving 80% Guidance CutSAN FRANCISCO,Dec. 3, 2025/PRNewswire/ -- National shareholder rights law firm**Hagens Berman**reminds investors that the deadline to move the Court for appointment as lead plaintiff in the securities class action lawsuit against**Inspire Medical Systems, Inc. (NYSE:[INSP](#financial- modal))**is**January 5, 2026.**The lawsuitallegesthat Inspire Medical and its executives misled investors b ...

SAN FRANCISCO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman reminds investors that the deadline to move the Court for appointment as lead plaintiff in the securities class action lawsuit against Inspire Medical Systems, Inc. (NYSE: INSP) is January 5, 2026. The lawsuit alleges that Inspire Medical and its executives misled investors by providing assurances of “operational readiness” for the Inspire V device launch, while concealing critical failures in billing softwar ...